Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
78.59
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc ADR
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
55
56
Next >
iPhone US Shipments Take A Hit, Does Social Media Algorithm Impact Political Beliefs? Research Reveals Answer, Disney Joins Netflix To Crack Down Password Sharing In India: Today's Top Stories
July 28, 2023
Bloomberg
Via
Benzinga
AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up
July 28, 2023
AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has
Via
Benzinga
US Stock Futures Signal Rebound On Tech Earnings Support: Analyst Tells Why Fed May Not Start Cutting Rates Anytime Soon
July 28, 2023
Stocks appear to have shaken off Thursday's negativity and are positioned for a rebound on upbeat earnings.
Via
Benzinga
AstraZeneca Earnings Preview
July 27, 2023
Via
Benzinga
This Is What Whales Are Betting On AstraZeneca
July 13, 2023
Via
Benzinga
A Look Into AstraZeneca's Debt
July 07, 2023
Via
Benzinga
AstraZeneca Unusual Options Activity
July 03, 2023
Via
Benzinga
Earnings Scheduled For July 28, 2023
July 28, 2023
Companies Reporting Before The Bell • Sanofi (NASDAQ:SNY) is likely to report quarterly earnings at $1.58 per share on revenue of $11.32 billion.
Via
Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
July 27, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Plummets, Sacrificing A Breakout, On Mixed Results In Lung Cancer Treatment
July 03, 2023
The company tested a treatment in combination with Daiichi Sankyo.
Via
Investor's Business Daily
Novo Nordisk's Diabetes, Weight Loss Drugs Under UK Scrutiny: Follows Suicidal Behavior Reports
July 26, 2023
The Medicines and Healthcare Products Regulatory Agency (MHRA), the U.K.'s drug regulatory authority, is reportedly scrutinizing a category of drugs used in diabetes medication and a weight loss...
Via
Benzinga
Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings
July 26, 2023
Argenx is up around 40% in 2023 after shares soared nearly 30% in a single day last week.
Via
Investor's Business Daily
Dow Jones Leads Weekly Gains As Tesla, Netflix Sell-Offs Dent Nasdaq; Big Banks Show Resilience To Volatility
July 21, 2023
Via
Benzinga
Why Pieris Pharmaceuticals Shares Shooting Higher Today?
July 18, 2023
Pieris Pharmaceuticals Inc (NASDAQ: PIRS) shares are trading higher after the company
Via
Benzinga
NBCUniversal's Peacock Raises Prices First Time Since Launch, Warren Buffett Sells Majority of Activision Blizzard Stake Before Microsoft Deal Approval, Novartis Launches $15B Share Buyback: Today's Top Stories
July 18, 2023
Wall Street Journal
Via
Benzinga
AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants
July 18, 2023
The FDA approved AstraZeneca Plc (NASDAQ:
Via
Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
July 17, 2023
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030.
Via
Benzinga
3 Doomed Biotech Stocks Destined for Disaster
July 17, 2023
Doomed biotech stocks are a major part of the natural cycle within the sector that results in a lot of failures.
Via
InvestorPlace
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
July 13, 2023
An overweight world is hungry for new treatments. For now, two companies own the market.
Via
Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
July 12, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
July 11, 2023
One in eight women will be diagnosed with breast cancer during
Via
Benzinga
What's Going On With Novavax (NVAX) Stock?
July 10, 2023
Novavax, Inc. (NASDAQ: NVAX) shares are trading higher on Monday after the company announced an amendment to its Canada supply agreement, under which the Government of Canada will pay Novavax $349.6...
Via
Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
July 07, 2023
Automakers rallied on sales while Meta's Threads had a big launch.
Via
Investor's Business Daily
Biotech Blues: Stay Balanced Through July Earnings Season
July 05, 2023
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts.
Via
Talk Markets
These Were Monday's 2 Stock Movers That Investors Cared About the Most
July 03, 2023
On a quiet day on Wall Street, a couple of stocks still saw a considerable amount of activity.
Via
The Motley Fool
AstraZeneca Losses Leave The FTSE In The Red To Start July
July 03, 2023
Despite reaching record highs earlier this year, the UK's FTSE 100 experienced a decline in the April-June period due to volatile commodity prices and persistent inflation concerns.
Via
Talk Markets
AstraZeneca, ECARX Holdings And Other Big Stocks Moving Lower On Monday
July 03, 2023
U.S. stocks traded mixed, with the Dow Jones dropping around 30 points on Monday. Here are some big stocks recording losses in today’s session. Protagonist Therapeutics, Inc. (NASDAQ: PTGX) shares...
Via
Benzinga
Datopotamab Deruxtecan Met Dual Primary Endpoint of Progression-Free Survival in Patients With Advanced Non-Small Cell Lung Cancer in TROPION-Lung01 Phase III Trial
July 03, 2023
From
AstraZeneca
Via
Business Wire
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...
Via
Benzinga
4 Unparalleled Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
July 01, 2023
Bargains abound with the innovation-driven Nasdaq Composite still well below its all-time high.
Via
The Motley Fool
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
55
56
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.